EUVIMEDEUVIMED entdecken
Crossref

Beyond The Skin: Prolactin in Psoriasis as a Biomarker of Disease Severity

Sonali Sonali, Kallappa C. Herakal

International Journal of Current Pharmaceutical Review and Research · 30.06.2026 · 18 (06)

DOI: 10.25258/ijcpr.18.6.141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.06.2026. Verfasst von Sonali Sonali und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Psoriasis is a long-term immune-mediated skin condition marked by keratinocyte hyperproliferation. The anterior pituitary secretes the multifunctional neuropeptide hormone prolactin, which has been linked to immunological regulation and keratinocyte proliferation, indicating a possible role in the pathogenesis of psoriasis. There are still few data from the Indian subcontinent despite several studies conducted worldwide. Objectives: to compare psoriasis patients' blood prolactin levels to those of controls and to establish a correlation between prolactin levels and clinical metrics such as disease severity indicators (PASI and BSA).

Methods

A case-control study was conducted at Navodaya Medical College, Hospital & Research Centre, Raichur, from February 2024 to June 2025. A total of 140 participants, 70 psoriasis patients and 70 age- and sex-matched controls were enrolled. Serum prolactin levels were measured and correlated with epidemiological variables, BSA, and PASI scores using independent t-test, Chi-square test, ANOVA, and Pearson/Spearman correlation analysis.

Results

The mean serum prolactin level was significantly higher in cases (13.24 ± 9.12 ng/mL) compared to controls (6.84 ± 2.91 ng/mL; p < 0.001). Elevated prolactin was observed in 15 cases (21.4%) compared to only 4 controls (5.7%). Female patients exhibited significantly higher prolactin levels (18.62 ± 13.07 ng/mL) than males (11.03 ± 6.24 ng/mL; p = 0.003). Prolactin levels were associated significantly with PASI score (p = 0.001) and BSA (p = 0.041). The highest mean prolactin was noted in the PASI 41–55 group (19.84 ± 12.43 ng/mL).

Conclusion

Psoriasis patients have significantly higher serum prolactin levels, which are correlated with the severity of the condition as determined by PASI and BSA. Prolactin should be taken into account in the immunopathogenesis of psoriasis and may be a clinically available biomarker for tracking its severity.

Zitieren

APA

Sonali, S., & Herakal, K. C. (2026). Beyond The Skin: Prolactin in Psoriasis as a Biomarker of Disease Severity. International Journal of Current Pharmaceutical Review and Research, 18(06). https://doi.org/10.25258/ijcpr.18.6.141

Vancouver

Sonali S, Herakal KC. Beyond The Skin: Prolactin in Psoriasis as a Biomarker of Disease Severity. International Journal of Current Pharmaceutical Review and Research. 2026;18(06). doi:10.25258/ijcpr.18.6.141

BibTeX
@article{Sonali2026,
  author = {Sonali, Sonali and Herakal, Kallappa C.},
  title = {Beyond The Skin: Prolactin in Psoriasis as a Biomarker of Disease Severity},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {06},
  doi = {10.25258/ijcpr.18.6.141}
}
Kostenlos starten →